In an era where the biopharmaceutical industry faces unprecedented pressure to accelerate time-to-market while maintaining rigorous safety standards, FUJIFILM Biotechnologies is positioning itself as a leader in the evolution of contract development and manufacturing (CDMO). At the heart of this transformation is a massive $7 billion global expansion initiative and a bold leadership philosophy spearheaded by Chief Operating Officer Maja Herold Pedersen. By bridging the gap between historical quality-centric mindsets and the operational agility required by modern AI, Pedersen is steering the company toward a future where "innovation at speed" is not just a catchphrase, but an operational reality.
The Infrastructure of Growth: A Global Footprint
FUJIFILM Biotechnologies is currently engaged in one of the most ambitious capital investment cycles in the history of the bioprocessing sector. With $7 billion committed across the United States and Europe, the company is systematically building a resilient, interconnected network of manufacturing sites designed to meet the growing demand for complex biologics and advanced therapies.
Key Expansion Milestones:
- North Carolina, USA: The centerpiece of the strategy is the $3.2 billion Holly Springs facility. The site successfully brought its first phase online in September 2025, with a second phase of development already slated for 2028.
- Hillerød, Denmark: The company is significantly scaling its Danish campus, incorporating eight additional 20,000-liter bioreactors and two new downstream processing streams.
- Teesside, UK: In early 2026, the company inaugurated the United Kingdom’s largest single-use CDMO facility, further diversifying its manufacturing capabilities.
- Madison, Wisconsin, USA: Through its subsidiary, FUJIFILM Cellular Dynamics, the company opened a new induced pluripotent stem cell (iPSC) manufacturing headquarters in May 2026. This $200 million investment is projected to quadruple the company’s cell-production capacity, marking a significant step forward in the scalability of regenerative medicine.
These sites are bound together by kojoX, a proprietary modular bioproduction framework. Derived from the Japanese term kojo ("factory" and "improvement") and the "X" of exponential growth, kojoX enforces standard equipment, processes, and quality systems across all global sites. This standardization allows for the seamless transfer of validated drug-substance processes, drastically reducing the traditional regulatory and tech-transfer bottlenecks that often plague the biopharma industry.
The Path from Quality to Operations
The transition of Maja Herold Pedersen from Chief Quality Officer to Chief Technology Officer, and finally to Chief Operating Officer in September 2025, reflects the company’s strategic shift. For Pedersen, the distinction between "quality" and "operations" is a false dichotomy.
"I’ve never been a quality-function-only leader," Pedersen explains. "I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat; we need to make this work for patients in the end."
Pedersen’s career trajectory is rooted in a fundamental appreciation for the patient experience. Her early years in regulatory roles and patient advocacy groups provided her with a visceral understanding of the clinical stakes involved in manufacturing. This perspective continues to inform her leadership: she views the "quality-to-operations" path not as a career ladder, but as an integrated approach to ensuring that safety, compliance, and velocity are treated as mutually reinforcing goals rather than competing interests.
Industrializing AI: Moving Beyond Pilots
In many pharmaceutical settings, artificial intelligence remains confined to isolated, small-scale pilot projects. Pedersen is aggressively pushing to change that narrative at FUJIFILM Biotechnologies. Recognizing that the industry’s risk-averse nature—rightfully focused on validation and deterministic outcomes—often stifles innovation, she has championed an internal, secure AI ecosystem.
The GenkiBot Initiative
To avoid the security and compliance risks associated with public-facing AI tools, Pedersen oversaw the development of "GenkiBot," an internal AI platform named after the Japanese word for enthusiasm and vitality.
GenkiBot serves as a secure, company-wide environment where employees can utilize generative AI without risking proprietary data leakage. The platform is currently being deployed to automate complex tasks, such as:
- Deviation Management: AI agents now assist in drafting deviations, coaching Subject Matter Experts (SMEs) on standard procedures, and performing root-cause analyses by synthesizing vast amounts of historical data.
- Efficiency Metrics: Currently, roughly 50% of deviation reports are handled via GenkiBot, with a target of 100% adoption.
"We can’t make it something people may do if they want to," Pedersen notes. "This is a change I think we all have to adapt to."
Scaling Agentic Tools: The Philosophy of Freedom
One of the most profound challenges in the regulated biopharma space is how to scale agentic AI—systems that can perform tasks autonomously—without sacrificing the "human-in-the-loop" necessity of GMP (Good Manufacturing Practice).
Pedersen proposes a tiered approach to AI scaling. She argues that instead of "boxing in" AI, the organization should foster a culture of widespread, low-stakes experimentation. By equipping employees with the ability to "code" their own agents—akin to the era when macros in Excel revolutionized administrative work—the company can build a massive, decentralized funnel of innovation.
"I’m a big believer that scaling only follows the actual speed if we set it free," she says. "If we equip everyone with the ability to do that kind of coding, then only the ones that are verified and can be maintained will end up in the queue of agents that interact with GMP decisions."
This approach—a "playful" yet controlled decentralization—is admittedly counter-intuitive for a traditional pharmaceutical firm. However, Pedersen believes that the complexity of modern biologics leaves no room for slow, top-down decision-making.
Cultural Transformation: The 9 People Fundamentals
The technical and structural shifts at FUJIFILM Biotechnologies are underpinned by a cultural framework known as the "9 People Fundamentals." This philosophy is designed to dismantle the silos of traditional hierarchy and empower individual decision-making.
The fundamentals focus on:
- Empowerment: Setting employees free to make decisions within their domain.
- Accountability: Balancing freedom with a high degree of personal responsibility.
- Authenticity: Encouraging employees to bring their full selves to the work environment.
Pedersen compares the organizational structure to a biological organism. "We have our brain, and then we have numerous cells out in the body, and they actually work very well individually. Of course, there’s a brain structure that makes it all flow in one direction, so the cells don’t all go off and do their own thing. But the immediacy of what each individual can do when they’re set free—that’s what we need in the future."
This cultural evolution is being reinforced through the "Leaders for Life" cohort, an intensive program that forces leaders to reflect on their psychological reactions and their impact on the surrounding team. For Pedersen, empowering the workforce is not just about employee satisfaction—it is a strategic necessity for managing the massive growth the company is currently undergoing.
Implications for the Future of CDMOs
The implications of Pedersen’s work at FUJIFILM Biotechnologies are far-reaching. As the industry moves toward more personalized medicine and high-throughput manufacturing, the traditional model of rigid, slow-moving operations is becoming obsolete.
By integrating AI, standardizing global operations via the kojoX framework, and cultivating a culture of high-autonomy leadership, FUJIFILM is creating a blueprint for the "Next-Gen CDMO." The success of this model will likely be measured by the company’s ability to compress technology transfer timelines and maintain its impeccable quality record while significantly scaling output.
As Pedersen continues to push the boundaries of what is possible in a regulated environment, the biopharmaceutical sector will be watching closely. Her blend of deep regulatory respect and radical operational impatience suggests that the path to the future of medicine is not found in choosing between safety and speed, but in re-engineering the organization to achieve both simultaneously.
About the Author
